Document is current
Any future updates will be listed below
-
Authors
Zhang, Linyao
Kang, Xiaoyu
Wang, Qianhui
Cao, Zijie
Gao, Ruixin
Yu, Yan
Li, Ting
Liu, Lixu
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82271427)
National Key R&D Program of China (2022YFC3602802)
Scientific Research Foundation of China Rehabilitation Research Center (2022ZX-08)
- License Information
-
More Information
Article History
Received: 21 December 2025
Accepted: 11 February 2026
First Online: 26 February 2026
Declarations
:
: The authors declare no competing interests.
: The cell line used in this study ( HT22 ) was purchased from the Guangzhou Jiniou Biotechnology Co., Ltd. and is commercially available and de-identified. The study only involved in vitro cell culture and did not include any in vivo animal experiments or human clinical trials. According to the regulations of our institution’s ethics committee, studies using commercialized, non-primary cell lines do not require additional animal or human ethics approval.
